UPDATES IN HEPATITIS C
|
|
- Jonah Adams
- 6 years ago
- Views:
Transcription
1 UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient education on sofosbuvir and simeprevir STATISTICS Prevalence 2.7 million to 3.9 million persons in the US 45-85% are unaware that they are infected Most prevalent in those born from Most likely infected during the 1970s-1980s Accessed 3/25/2014 1
2 BEHAVIORAL RISK FACTORS Injection drug use Blood transfusions (prior to 1992) Needle stick injuries in health care settings From pregnant mother to child Sex with an infected person Ineffective means of transmission Sharing personal items Ineffective means of transmission Accessed 3/25/2014 COMPLICATIONS If100 people become infected with Hepatitis C will go on to develop chronic infection will go on to develop chronic liver disease 5 20 will go on to develop cirrhosis over a period of years 1 5 will die from the consequences of chronic infection (liver cancer or cirrhosis) Chronic hepatitis C is the leading indication for liver transplants in the US Accessed 3/25/2014 GENOTYPES Genotype1 US (60-70%) and Europe Genotype 2 US, Europe, Asia, South America, Africa Genotype 3 India, Far East and Australia Genotype 4 Africa and Middle East Genotype 5 South Africa Genotype 6 Hong Kong, Vietnam and Australia Chopra, S. Characteristics of the hepatitis C virus. In: UpToDate, Bloom, A (Ed), UpToDate, Waltham, MA
3 Accessed April 2, TREATMENT Past Present Future TREATMENT PAST 3
4 TREATMENT TIMELINE 1957 Discovery of antiviral properties of interferon 1989 Discovery of hepatitis C virus FDA approves first alfa interferon for treatment of hepatitis C Injected 3 times weekly x 48 weeks Rebetron approved (alfa interferon and ribavirin) Injected 3 times weekly x weeks given with ribavirin HCV Advocate A Brief History of Hepatitis C. Accessed 4/1/2014 TREATMENT TIMELINE Peg-Intron approved (pegylated interferon alpha-2b) Peg-Intron plus ribavirin approved Inject 1 time weekly Pegasys approved (pegylated interferon alpha-2a) Inject 1 time weekly Protease inhibitors approved (telaprevir and boceprevir) Used in combination with pegylated interferon and ribavirin Approved for genotype 1 only HCV Advocate A Brief History of Hepatitis C. [Last accessed ] Accessed April 3,
5 TREATMENT RESPONSE Yee, HS, et al. (2012) Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 107: TREATMENT PRESENT Accessed April 3,
6 GUIDANCE Recommendations for Testing, Managing, and Treating Hepatitis C hcvguidelines.org AASLD/IDSA This guidance should be considered a living document NS3/4A PROTEASE INHIBITORS Inhibitors of NS3/4A serine protease Enzyme involved in post-translational processing and replication of hepatitis C virus (HCV) Disrupt HCV by blocking the NS3 catalytic site or the NS3/4A interaction Blocks TRIF-mediated Toll-like receptor signaling and Cardifmediated retinoic acid-inducible gene 1 signaling 1 st Generation Boceprevir Telaprevir 2 nd Generation simeprevir Pockros, P. Direct acting antivirals for the treatment of hepatitis c virus infection. In: UpToDate, Bloom, A (Ed), UpToDate, Waltham, MA BOCEPREVIR 800 mg TID (available in 200 mg tablets) 12 tablets daily Approved for genotype 1 only Used in combination with peginterferon and ribavirin Treatment guided by an algorithm 6
7 Yee, HS, et al. (2012) Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 107: TELAPREVIR 1125 mg BID (available in 375mg tablets) 6 tablets daily Must be taken with 20 grams of fat Approved for genotype 1 only Used in combination with peginterferon and ribavirin Treatment guided by an algorithm Yee, HS, et al. (2012) Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 107:
8 SIMEPREVIR Approved November 2013 Genotype 1 patients with compensated liver disease (including cirrhosis) in combination with peginterferon alfa and ribavirin 150 mg once daily with food Food increases absorption by ~65% NS3 Q80K polymorphism Specific to genotype 1a subgroup If present, reduces efficacy of simeprevir Contains a sulfonamide moiety Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December SIMEPREVIR ADMINISTRATION Treatment-naïve and prior relapse patients including those with cirrhosis Prior non-responder patients (including partial and null responders) including those with cirrhosis Simeprevir + peg + ribavirin First 12 weeks First 12 weeks Peg + ribavirin Additional 12 weeks Additional 36 weeks Total Duration 24 weeks 48 weeks Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December SIMEPREVIR STOPPING RULES HCV RNA Treatment week 4: Greater than or equal to 25 IU/ml Treatment week 12: Greater than or equal to 25 IU/ml Treatment week 24: Greater than or equal to 25 IU/ml Action Discontinue simeprevir, peg and ribavirin Discontinue peg and ribavirin -simeprevir is complete at week 12 Discontinue peg and ribavirin *If peg or ribavirin is stopped for any reason simeprevir must be discontinued Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December
9 SIMEPREVIR DRUG INTERACTIONS Metabolized by CYP3A Mildly inhibits CYP1A2 and intestinal CYP3A4 CYP 3A Inhibitors CYP 3A Inducers EFFECT ON SIMEPREVIR CONCENTRATIONS INCREASES Increased risk of ADRs DECREASES Risk of reduced efficacy SELECT EXAMPLE Macrolides, antifungals, milk thistle, ritonavir Anticonvulsants, rifampin, dexamethasone, st johns wort, efavirenz SIMEPREVIR SPECIAL POPULATIONS Pregnancy category C Ribavirin is category X Hepatic Impairment No dose recommendation for patients with moderate or severe hepatic impairment Has not been studied post liver transplant Renal Impairment Not studied in CrCl <30 ml/min Race East Asian ancestry experience increased exposure No dose recommendations Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December SIMEPREVIR WARNINGS Photosensitivity Most frequently occurs in the first 4 weeks of treatment Exaggerated sunburn in areas exposed to light Use sun protection measures Rash Most frequently occurs in the first 4 weeks of treatment Most are mild to moderate and do not require discontinuation of simeprevir Sulfa allergy No increased incidence of rash or photosensitivity Insufficient evidence Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December
10 SIMEPREVIR ADRS ADR Simeprevir + peg-ifn + ribavirin First 12 weeks N=781 %(n) Rash/photosensitivity 28(218) 20(79) Pruritus 22(168) 15(58) Nausea 22(173) 18(70) Myalgia 16(126) 13(53) Dyspnea 12(92) 8(30) Placebo + peg-ifn + ribavirin First 12 weeks N=397 %(n) Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December SIMEPREVIR PATIENT EDUCATION Should not be taken alone Females and males must use 2 forms of birth control during treatment and 6 months after Missed dose take within 12 hours of missing the dose Photosensitivity Rash Store in original bottle POOLED QUEST 1 & QUEST 2 Phase III Not yet published Genotype 1, treatment naïve, with compensated liver disease including cirrhosis N=785 Simep + peg-ifn + riba Peg-IFN + riba Genotype 1 419/521 (80%) 133/264 (50%) Genotype 1a 191/254 (75%) 63/131 (48%) Without Q80K 138/165 (84%) 36/83 (43%) With Q80K 49/84 (58%) 24/44 (55%) Genotype 1b 228/267 (85%) 70/133 (53%) Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December
11 POOLED QUEST 1 & QUEST 2 Subgroup METAVIR Fibrosis Score Subgroup Simep + peg-ifn + riba % (n/n) Peg-IFN + riba % (n/n) F (317/378) 55 (106/192) F (89/130) 36 (26/72) Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December PROMISE Phase III, not yet published Genotype 1, relapsed following previous interferon based therapy, with compensated liver disease including cirrhosis N=393 Simep + peg-inf +riba Peg-IFN + riba Genotype 1 26/260 (79%) 48/133 (36%) Genotype 1a 78/111 (70%) 14/54 (26%) Without Q80K 62/79 (78%) 8/34 (24%) With Q80K 14/30 (47%) 6/20 (30%) Genotype 1b 128/149 (86%) 34/79 (43%) Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December PROMISE Subgroup METAVIR Fibrosis Score Subgroup Simep + peg-ifn + riba % (n/n) Peg-IFN + riba % (n/n) F (137/167) 41 (40/98) F (61/83) 24 (8/34) Olysio[package insert]. Titusville, NJ: Janssen Therapeutics; December
12 ASPIRE Phase 2b Genotype 1, failed prior therapy with peg-ifn and ribavirin Simep 150 mg x 12 w + PR SVR24 % (n/n) Pooled simep 100 mg and 150 mg x 12w + PR SVR24 % (n/n) Placebo + PR SVR24 % (n/n) Prior relapser 77 (20/26) 83 (44/53) 37 (10/27) Prior partial responder Prior null responder 65 (15/23) 67 (31/46) 9 (2/23) 53 (9/17) 45 (15/33) 19 (3/16) Zeuzem S, Berg T, Gane E, et al. Simeprevir Increases Rate of Sustained Virologic Response Among Treatment- Experienced Patients with HCV Genotype-1 Infection: a Phase IIb Trial. Gastroenterology. 2013a ASPIRE Q80K polymorphism Genotype 1a Simep 150 mg + PR SVR24 Without Q80K 66.1% (39/59) With Q80K 60.9% (14/23) NS5B POLYMERASE INHIBITOR NS5B is an RNA dependent RNA polymerase involved in post translational processing Necessary for replication of HCV Enzyme has a catalytic site for nucleoside binding Sofosbuvir Pockros, P. Direct acting antivirals for the treatment of hepatitis c virus infection. In: UpToDate, Bloom, A (Ed), UpToDate, Waltham, MA
13 SOFOSBUVIR Approved December 2013 Approved for use in genotypes 1, 2, 3, and 4 Nucleotide analog NS5B polymerase inhibitor 400 mg once daily with or without food Dispense in original container Sovaldi [package insert]. Foster City; Gilead Sciences; December SOFOSBUVIR ADMINISTRATION Genotype Treatment Duration Genotype 1or 4 sofosbuvir + peg-ifn + ribavirin 12 weeks Genotype 2 sofosbuvir + ribavirin 12 weeks Genotype 3 Sofosbuvir + ribavirin 24 weeks Genotype 1 ineligible for peg-ifn Patients with hepatocellular carcinoma awaiting liver transplant Sofosbuvir + ribavirin Sofosbuvir + ribavirin 24 weeks Up to 48 weeks or until the time of liver transplant, whichever occurs first Sovaldi [package insert]. Foster City; Gilead Sciences; December SOFOSBUVIR DRUG INTERACTIONS Substrate of P-gp Inducers may decrease sofosbuvir plasma concentrations and decrease its therapeutic effects Do NOT coadminister decreases sofosbuvir concentrations Anticonvulsants Rifampin St. John s wort Tipranavir/ritonavir Drugs WITHOUT clinically significant interactions Cyclosporine Darunavir/ritonavir Efavirenz Emtricitabine Methadone Raltegravir Rilpivirine Tacrolimis Tenofovir Sovaldi [package insert]. Foster City; Gilead Sciences; December
14 SOFOSBUVIR SPECIAL POPULATIONS Pregnancy category B Ribavirin is category X Hepatic Impairment No dose adjustments needed for patients with mild, moderate or severe hepatic impairment Has not been studied post liver transplant Renal Impairment Not studied in CrCl <30 ml/min Sovaldi [package insert]. Foster City; Gilead Sciences; December SOFOSBUVIR ADRS Sovaldi [package insert]. Foster City; Gilead Sciences; December SOFOSBUVIR PATIENT EDUCATION Should not be taken alone Females and males must use 2 forms of birth control during treatment and 6 months after Keep in original container Take missed dose as soon remembered, but not more than 2 doses in one day Sovaldi [package insert]. Foster City; Gilead Sciences; December
15 NEUTRINO 12 weeks of sofosbuvir + peg-ifn + ribavirin in treatment naïve subjects with compensated liver disease including cirrhosis Genotypes 1 and 4 Phase 3 trial N=327 Genotype SVR Overall SVR 90% (295/327) 1 89% (261/292) 1a 92% (206/225) 1b 82% (54/66) 4 96% (27/28) Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013b;368(20): NEUTRINO Selected subgroups Subgroup SVR Cirrhosis No 92% (252/273) Yes 80% (43/54) Race Black 87% (47/54) Non-black 91% (248/273) Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013b;368(20): FISSION Genotypes 2 and 3, treatment naive Sofosbuvir + ribavirin for 12 weeks compared to peg-ifn + ribavirin for 24 weeks Phase 3 Genotype Sof + riba X 12 weeks N=253 peg/riba x 24 weeks N=243 Overall 2 & 3 67% (170/253) 67% (162/243) 2 95% (69/76) 78% (52/67) 3 56% (102/183) 63% (110/176) Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013b;368(20):
16 FISSION Selected subgroup Cirrhosis Genotype 2 Genotype 3 Sof + riba X 12 w Peg + riba X 24 w Sof + riba X 12 w Peg + riba X 24 w Without 97% (59/61) 81% (44/54) 61% (89/145) 71%(99/139) With 83% (10/12) 62% (8/13) 34% (13/38) 30% (11/37) Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013b;368(20): POSITRON Sofosbuvir + ribavirin x 12 weeks Genotypes 2 and 3 Patients who are interferon intolerant, ineligible or unwilling with compensated liver disease including cirrhosis Phase 3, placebo controlled Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20): POSITRON Genotype Sofosbuvir + riba x 12 weeks N=207 Placebo X 12 weeks N=71 Difference [95% CI] Overall 2 & 3 78% (161/207) 0/71 78% [71,84] 2 93% (101/109) 0/34 93% [88,98] 3 61% (60/98) 0/37 61% [52,71] Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):
17 POSITRON Selected subgroups Cirrhosis Sofosbuvir + riba X 12 weeks Genotype 2 N=109 Sofosbuvir + riba X 12 weeks Genotype 3 N=109 No 92% (85/92) 68% (57/84) Yes 94% (16/17) 21% (3/14) Interferon Ineligible 88% (36/41) 70% (33/47) Intolerant 100% (9/9) 50% (4/8) Unwilling 95% (56/59) 53% (23/43) Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20): FUSION Sofosbuvir and ribavirin for 12 or 16 weeks Phase 3 Genotype 2 or 3 who are treatment experienced with compensated liver disease including cirrhosis Genotype Sofos + riba X 12 weeks N=103 Sofos + riba X 16 weeks N=98 Difference [95% CI] Overall 50% (51/103) 71% (70/98) -22% [-35%,-9%] Genotype 2 82% (32/39) 59% (31/35) -7% [-23%,9%] Genotype 3 30% (19/64) 62% (39/63) -32% [-49%,-16%] Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20): TREATMENT FU TU RE 17
18 SIMEPREVIR + SOFOSBUVIR? Not FDA approved COSMOS On-going phase II trial Simeprevir 150 mg and sofosbuvir 400 mg daily with or without ribavirin for 12 or 24 weeks Genotype 1 Published abstract Jacobson IM, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Hepatology: Special Issue: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting ;58(4):1379A. COSMOS SVR4 Prior null responder to peg/riba and metavir score F0-2 Treatment naïve and prior null responders with metavir score F3-4 Prior null responder to peg/riba and metavir score F0-2 -w/ Q80K mutation Treatment naïve and prior null responders with metavir score F3-4 Sim + sofo w/o ribavirin X 12 weeks Sim + sofo w/ ribavirin X 12 weeks Sim + sofo w/o ribavirin X 24 weeks Sim + sofo w/ ribavirin X 24 weeks 13/14 (92.9%) 26/27 (96.3%) 14/15 (93.3%) 20/24 (83.3%) 14/14 (100%) 26/27 (96.3%) NA NA 13/14 (92.9%) 5/6 (83.3%) 26/27 (96.3%) 8/9/ (88.9%) 14/15 (93.3%) 4/4 (100%) NA NA NA NA 19/24 (79.2%) 8/12 (66.7%) DACLATASVIR NS5A replication complex inhibitor NS5A plays a role in viral replication and assembly of the hepatitis c virus Bristol-Myers Squibb 18
19 DACLATASVIR + SOFOSBUVIR Genotype 1, 2, 3 previously untreated patients sofosbuvir for 1 week, then daclatasvir and sofosbuvir for 23 weeks daclatasvir and sofosbuvir for 24 weeks daclatasvir, sofosbuvir, and ribavirin for 24 weeks Genotype 1 previous non responders to treatment with telaprevir or boceprevir daclatasvir plus sofosbuvir, with or without ribavirin, for 12 weeks daclatasvir plus sofosbuvir, with or without ribavirin, for 24 weeks Sulkowski, M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370: Sulkowski, M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370: DACLATASVIR + SOFOSBUVIR Genotype 1 Prev untreated Sofo + dac X 12 weeks Genotype 1 Failed boc or telap Sofo + dac X 24 wees Genotype 2 Sofo + dac X 24 weeks Genotype 3 Sofo + dac X 24 weeks 98% 98% 92% 89% Sulkowski, M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:
20 ASUNAPREVIR NS3/4A protease inhibitor DACLASTASVIR + ASUNAPREVIR phase 2a, open-label, 24-week treatment study daclatasvir 60 mg once-daily AND genotype 1b patients received asunaprevir 200mg twice or once-daily genotype 1a and genotype 1b patients received asunaprevir twice or once-daily plus PegIFN/RBV genotype 1a and genotype 1b patients received asunaprevir twice-daily plus ribavirin Lok, A. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol Mar;60(3): DACLASTASVIR + ASUNAPREVIR Lok, A. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol Mar;60(3):
21 LEDIPASVIR NS5A inhibitor SOFOSBUVIR + LEDIPASVIR LONESTAR Genotype 1 Treatment naïve and treatment experienced with a protease inhibitor Sofosbuvir 400 mg and ledipasvir 90 mg SOFOSBUVIR + LEDIPASVIR Cohort A: treatment-naive patients Cohort B: patients previously treated with protease inhibitors Sofosbuvir Sofosbuvir Sofosbuvir Sofosbuvir Sofosbuvir plus ledipasvir plus ledipasvir plus ledipasvir plus ledipasvir plus ledipasvir with ribavirin with ribavirin for 8 weeks for 12 weeks for 12 weeks for 8 weeks for 12 weeks (n=20) (n=19) (n=19) (n=21) (n=21) Treatment week 4 20 (100%; (100%; (100%; (95%; (100%; 84 End of treatment 20 (100%; (100%; (100%; (100%; (100%; 84 SVR4 20 (100%; (100%; (100%; (95%; (100%; (95%; (100%; * (95%; (95%; 74 Lawitz, E. Sofosbuvir and ledipasvirfixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomisedphase 2 trial. Lancet Feb 8;383(9916):
22 COST Treatment Cost Interferon <$20,000 Peg-IFN + ribavirin $27,000 Telaprevir $79,000 Boceprevir $78,000 Simeprevir $66,360 Sofosbuvir $84,000 Fairpricingcoalition.com Accessed April 3, 2014 QUESTIONS? THANK Y OU! 22
9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014
Sarah Naidoo, PharmD, BCPS September 26, 2014 Be able to discuss changes in hepatitis C treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationUpdates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today
Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationSimeprevir (Olysio) Drug Summary. Class and Mechanism. Table of Contents
Hepatitis C Online PDF created September 18, 2018, 1:01 pm Simeprevir (Olysio) Table of Contents Simeprevir Olysio Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationAbbreviated Class Update: Hepatitis C
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationTreatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy
Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationOlysio (simeprivir) Policy Number: Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018
Olysio (simeprivir) Policy Number: 5.01.604 Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Olysio (simeprivir)
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationPharmacokinetics1, 2, 3, 4 Tmax
Brand Name: Olysio Generic Name: Simeprevir Manufacturer: Janssen Therapeutics Drug Class: NSIII/IVA protease inhibitor Uses Labeled: hepatitis C infection (genotype I) Unlabeled: hepatitis C infection
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHTA: Models, Costs & Benefits.
HTA: Models, Costs & Benefits John.Cairns@lshtm.ac.uk Explicit evaluation of costs and benefits Advantages Potential for more consistent decision making Potential for more transparent decision making Facilitates
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information2018 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1127-9 Program Prior Authorization/Notification Medication Sovaldi (sofosbuvir) P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationHEPATITIS C TREATMENT UPDATE
HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More information